Pulmonary Drug Delivery Systems Market

Pulmonary Drug Delivery Systems Market Size, Share, Growth Analysis, By Product(Metered Dose Inhalers, Dry Powder Inhalers), By Application(Asthma, Cystic Fibrosis), By Distribution Channel(Retail Pharmacies, Hospital Pharmacies), By End-use(Hospitals & Clinics, Homecare), By Region(North America, Europe) - Industry Forecast 2023-2030


Report ID: UCMIG35I2122 | Region: Global | Published Date: Upcoming | Pages: 165 | Tables: 55 | Figures: 60

Pulmonary Drug Delivery Systems Market Insights

Market Overview:

The size of the global market for pulmonary drug delivery devices/systems, which was estimated at USD 36.5 billion in 2016, is projected to increase at a CAGR of 4.7% from 2017 to 2021. In the near future, it is anticipated that the prevalence of chronic respiratory disorders will rise, accelerating the demand for pulmonary drug delivery systems (PDDS).

Pulmonary Drug Delivery Systems Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
Get Sample

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Pulmonary Drug Delivery Systems Market is segmented by Product, Application, Distribution Channel, End-use, Region. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Pulmonary Drug Delivery Systems Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Product the market is segmented as, Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers,  Mesh, Vibrating, Static, Pneumatic, Vented, Breath Actuated, Ultrasonic, Accessories
  • Based on Application the market is segmented as, Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis, Others
  • Based on Distribution Channel the market is segmented as, Retail Pharmacies, Hospital Pharmacies, E-Commerce
  • Based on End-use the market is segmented as, Hospitals & Clinics, Homecare
  • Based on Region the market is segmented as, North America, Europe, Asia Pacific, Latin America

Regional Analysis:

Pulmonary Drug Delivery Systems Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Pulmonary Drug Delivery Systems Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
SPEAK TO AN ANALYST

Pulmonary Drug Delivery Systems Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Pulmonary Drug Delivery Systems Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Pulmonary Drug Delivery Systems Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Pulmonary Drug Delivery Systems Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Pulmonary Drug Delivery Systems Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • involved in the development of novel MDIs and the high acceptance rate of these devices in developing regions, such as Asia Pacific and Latin America, are some of the factors responsible for the revenue generated by this segment.
  • Dry Powder Inhaler (DPI) segment is anticipated to grow at a lucrative rate during the future period. Advantages such as cost-effectiveness, short administration, and preparation time, and others are anticipated to increase the use of these inhalers by end users. Due to technological advancements, DPI emerged as a preferred medical device for the treatment of a diverse range of respiratory disorders, which has in turn increased the utilization of these products. The abovementioned factors are likely to propel the growth of this segment.
  • Nebulizers are projected to grow at a steady rate over the future period. These devices are the most frequently used inhalation devices in hospitals. Nebulizers have a high adoption rate in home care and emergency medicine due to their benefits, such as greater comfort, administration of large dosage, and favorable reimbursement scenario, which is expected to help maintain a steady demand for this product segment.
  • The accessories segment is estimated to grow at a CAGR of 5.6% owing to the launch of new products and extensive R&D in this field. These products are necessary for efficient drug delivery to a patient’s lungs. Abovementioned factors are anticipated to support the segment development
  • Application Insights
  • The asthma segment held the dominant share in 2016. An effective inhalation therapy that uses DPIs and MDIs is considered to be the basis of asthma management. Owing to the high number of people affected by asthma, the demand, and usage of devices such as MDIs and DPIs for asthma management are increasing, boosting the growth of this application.
  • The dynamic growth of the COPD segment can be attributed to the high incidence and mortality of this disease. Favorable reimbursement policies for the treatment of COPD and a rise in the number of government and non-government organizations that provide COPD treatment are increasing revenue generated by this segment. Owing to these factors, the COPD segment is expected to grow consistently.
  • Treatment of allergic rhinitis involves the use of nasal sprays, dry powder inhalers, and allergy shots. According to the National Center for Health Statistics (NCHS), in 2016, 20 million adults aged more than 18 years and 6.1 million children in the U.S. were diagnosed with allergic rhinitis. Due to a large patient pool, the demand for PDDS devices is projected to increase, resulting in the development of this segment.
  • The other application segment is anticipated to exhibit progress owing to the rise in patients diagnosed with various chronic diseases. According to the CDC, in 2016, 29.4 million adults were diagnosed with sinusitis in the U.S. Treatment of such diseases demands the use of PDDS. These factors are expected to provide this segment growth opportunity.
  • Distribution Channel Insights
  • Hospital pharmacies segment held the dominant share of the PDDS in 2016 and is projected to continue its dominance in the future. Hospitals provide extensive treatments, care, quick reimbursements, and insurance policies owing to which patients prefer hospital pharmacies. Furthermore, an increased number of hospitalizations is expected to boost the growth of this segment.
  • Retail pharmacies are expected to show steady growth over the future period, owing to easy accessibility and affordability. Hospitals and clinics rely on retail pharmacies as a backup for medications. Moreover, most of the home care products are available in retail pharmacies. These factors are likely to be responsible for the constant growth of this segment.
  • E-commerce is anticipated to grow at a CAGR of 5.4% during the forecast period. Various factors such as improving healthcare infrastructure in developing regions and convenience of purchasing in comparison to retail or hospital pharmacies have supported the growth of this distribution channel to a great extent.
  • The trend of online purchasing and the demand for it is growing due to comfort, flexibility, and convenience, which is increasing the revenue generated by this segment. Moreover, online shopping offers discounts that benefit customers. These factors are expected to collectively boost the demand for online pharmacies.
  • End-use Insights
  • As of 2016, hospitals accounted for the largest revenue share of the PDDS. Hospitals are currently advancing in terms of technology usage. Technologically advanced medical devices are being extensively used in hospitals to improve point-of-care. Furthermore, hospitals also provide a wide array of treatments for various respiratory diseases.
  • In developed regions such as North America and Europe, hospitals also provide quick reimbursements for COPD treatment under the Medicare program. These facts are expected to stimulate the utilization of PDDS devices in hospital settings, leading to growth.
  • The home care segment is expected to exhibit lucrative growth over the future period. Growing preference for home healthcare is expected to boost the use of PDDS devices in home care settings. An increase in the cost of health care services and a shortage of healthcare facilities have also led to an increase in demand for home care services.
  • The introduction of technologically advanced devices, which are portable and small-sized, has resulted in patients using such products at home. These devices are convenient, easy-to-use, and do not require any special training to operate. These associated advantages are expected to increase the adoption of PDDS in home care, thereby boosting the growth of this segment.
  • Regional Insights
  • North America held the dominant share of PDDS and was valued at USD 14.9 billion in 2016. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. A rise in the number of patients affected by these diseases, increases the demand for diagnostic devices, such as PDDS, thereby boosting the growth of this region.
  • In addition, the local presence of key pharmaceutical and medical devices players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America respiratory drug delivery devices market.
  • Asia Pacific region is anticipated to grow at an exponential rate of 6.2% due to the high prevalence of COPD, which indicates a substantial socioeconomic burden in this region. Continuous increase in the number of asthmatic and allergic rhinitis patients is also a major factor that is anticipated to propel the market demand for PDDS in the Asia Pacific region during the forecast period.
  • Furthermore, a rise in the number of supportive nongovernment organizations, such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), is estimated to increase awareness about the treatment of respiratory disorders amongst patients, leading to market growth. Continuous increase in R&D activities by key market players to develop novel respiratory devices is also expected to support the growth of the Asia Pacific region.
  • KEY MARKET SEGMENTS
  • By Product
  • Metered Dose Inhalers
  • Dry Powder Inhalers
  • Nebulizers
  •  Mesh
  • Vibrating
  • Static
  • Pneumatic
  • Vented
  • Breath Actuated
  • Ultrasonic
  • Accessories
  • By Application
  • Asthma
  • Cystic Fibrosis
  • COPD
  • Allergic Rhinitis
  • Others
  • By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • E-Commerce
  • By End-use
  • Hospitals & Clinics
  • Homecare
  • By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  • KEY PLAYERS
  • GlaxoSmithKline plc
  • Philips Respironics
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • 3M Healthcare
  • GF Health Products, Inc.
  • Merck & Co., Inc.
  • AstraZeneca

SkyQuest's Expertise:

The Pulmonary Drug Delivery Systems Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Product - Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers,  Mesh, Vibrating, Static, Pneumatic, Vented, Breath Actuated, Ultrasonic, Accessories
  • By Application - Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis, Others
  • By Distribution Channel - Retail Pharmacies, Hospital Pharmacies, E-Commerce
  • By End-use - Hospitals & Clinics, Homecare
  • By Region - North America, Europe, Asia Pacific, Latin America
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • involved in the development of novel MDIs and the high acceptance rate of these devices in developing regions, such as Asia Pacific and Latin America, are some of the factors responsible for the revenue generated by this segment.
  • Dry Powder Inhaler (DPI) segment is anticipated to grow at a lucrative rate during the future period. Advantages such as cost-effectiveness, short administration, and preparation time, and others are anticipated to increase the use of these inhalers by end users. Due to technological advancements, DPI emerged as a preferred medical device for the treatment of a diverse range of respiratory disorders, which has in turn increased the utilization of these products. The abovementioned factors are likely to propel the growth of this segment.
  • Nebulizers are projected to grow at a steady rate over the future period. These devices are the most frequently used inhalation devices in hospitals. Nebulizers have a high adoption rate in home care and emergency medicine due to their benefits, such as greater comfort, administration of large dosage, and favorable reimbursement scenario, which is expected to help maintain a steady demand for this product segment.
  • The accessories segment is estimated to grow at a CAGR of 5.6% owing to the launch of new products and extensive R&D in this field. These products are necessary for efficient drug delivery to a patient’s lungs. Abovementioned factors are anticipated to support the segment development
  • Application Insights
  • The asthma segment held the dominant share in 2016. An effective inhalation therapy that uses DPIs and MDIs is considered to be the basis of asthma management. Owing to the high number of people affected by asthma, the demand, and usage of devices such as MDIs and DPIs for asthma management are increasing, boosting the growth of this application.
  • The dynamic growth of the COPD segment can be attributed to the high incidence and mortality of this disease. Favorable reimbursement policies for the treatment of COPD and a rise in the number of government and non-government organizations that provide COPD treatment are increasing revenue generated by this segment. Owing to these factors, the COPD segment is expected to grow consistently.
  • Treatment of allergic rhinitis involves the use of nasal sprays, dry powder inhalers, and allergy shots. According to the National Center for Health Statistics (NCHS), in 2016, 20 million adults aged more than 18 years and 6.1 million children in the U.S. were diagnosed with allergic rhinitis. Due to a large patient pool, the demand for PDDS devices is projected to increase, resulting in the development of this segment.
  • The other application segment is anticipated to exhibit progress owing to the rise in patients diagnosed with various chronic diseases. According to the CDC, in 2016, 29.4 million adults were diagnosed with sinusitis in the U.S. Treatment of such diseases demands the use of PDDS. These factors are expected to provide this segment growth opportunity.
  • Distribution Channel Insights
  • Hospital pharmacies segment held the dominant share of the PDDS in 2016 and is projected to continue its dominance in the future. Hospitals provide extensive treatments, care, quick reimbursements, and insurance policies owing to which patients prefer hospital pharmacies. Furthermore, an increased number of hospitalizations is expected to boost the growth of this segment.
  • Retail pharmacies are expected to show steady growth over the future period, owing to easy accessibility and affordability. Hospitals and clinics rely on retail pharmacies as a backup for medications. Moreover, most of the home care products are available in retail pharmacies. These factors are likely to be responsible for the constant growth of this segment.
  • E-commerce is anticipated to grow at a CAGR of 5.4% during the forecast period. Various factors such as improving healthcare infrastructure in developing regions and convenience of purchasing in comparison to retail or hospital pharmacies have supported the growth of this distribution channel to a great extent.
  • The trend of online purchasing and the demand for it is growing due to comfort, flexibility, and convenience, which is increasing the revenue generated by this segment. Moreover, online shopping offers discounts that benefit customers. These factors are expected to collectively boost the demand for online pharmacies.
  • End-use Insights
  • As of 2016, hospitals accounted for the largest revenue share of the PDDS. Hospitals are currently advancing in terms of technology usage. Technologically advanced medical devices are being extensively used in hospitals to improve point-of-care. Furthermore, hospitals also provide a wide array of treatments for various respiratory diseases.
  • In developed regions such as North America and Europe, hospitals also provide quick reimbursements for COPD treatment under the Medicare program. These facts are expected to stimulate the utilization of PDDS devices in hospital settings, leading to growth.
  • The home care segment is expected to exhibit lucrative growth over the future period. Growing preference for home healthcare is expected to boost the use of PDDS devices in home care settings. An increase in the cost of health care services and a shortage of healthcare facilities have also led to an increase in demand for home care services.
  • The introduction of technologically advanced devices, which are portable and small-sized, has resulted in patients using such products at home. These devices are convenient, easy-to-use, and do not require any special training to operate. These associated advantages are expected to increase the adoption of PDDS in home care, thereby boosting the growth of this segment.
  • Regional Insights
  • North America held the dominant share of PDDS and was valued at USD 14.9 billion in 2016. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. A rise in the number of patients affected by these diseases, increases the demand for diagnostic devices, such as PDDS, thereby boosting the growth of this region.
  • In addition, the local presence of key pharmaceutical and medical devices players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America respiratory drug delivery devices market.
  • Asia Pacific region is anticipated to grow at an exponential rate of 6.2% due to the high prevalence of COPD, which indicates a substantial socioeconomic burden in this region. Continuous increase in the number of asthmatic and allergic rhinitis patients is also a major factor that is anticipated to propel the market demand for PDDS in the Asia Pacific region during the forecast period.
  • Furthermore, a rise in the number of supportive nongovernment organizations, such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), is estimated to increase awareness about the treatment of respiratory disorders amongst patients, leading to market growth. Continuous increase in R&D activities by key market players to develop novel respiratory devices is also expected to support the growth of the Asia Pacific region.
  • KEY MARKET SEGMENTS
  • By Product
  • Metered Dose Inhalers
  • Dry Powder Inhalers
  • Nebulizers
  •  Mesh
  • Vibrating
  • Static
  • Pneumatic
  • Vented
  • Breath Actuated
  • Ultrasonic
  • Accessories
  • By Application
  • Asthma
  • Cystic Fibrosis
  • COPD
  • Allergic Rhinitis
  • Others
  • By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • E-Commerce
  • By End-use
  • Hospitals & Clinics
  • Homecare
  • By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  • KEY PLAYERS
  • GlaxoSmithKline plc
  • Philips Respironics
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • 3M Healthcare
  • GF Health Products, Inc.
  • Merck & Co., Inc.
  • AstraZeneca
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Pulmonary Drug Delivery Systems Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Pulmonary Drug Delivery Systems Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • involved in the development of novel MDIs and the high acceptance rate of these devices in developing regions, such as Asia Pacific and Latin America, are some of the factors responsible for the revenue generated by this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Dry Powder Inhaler (DPI) segment is anticipated to grow at a lucrative rate during the future period. Advantages such as cost-effectiveness, short administration, and preparation time, and others are anticipated to increase the use of these inhalers by end users. Due to technological advancements, DPI emerged as a preferred medical device for the treatment of a diverse range of respiratory disorders, which has in turn increased the utilization of these products. The abovementioned factors are likely to propel the growth of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Nebulizers are projected to grow at a steady rate over the future period. These devices are the most frequently used inhalation devices in hospitals. Nebulizers have a high adoption rate in home care and emergency medicine due to their benefits, such as greater comfort, administration of large dosage, and favorable reimbursement scenario, which is expected to help maintain a steady demand for this product segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The accessories segment is estimated to grow at a CAGR of 5.6% owing to the launch of new products and extensive R&D in this field. These products are necessary for efficient drug delivery to a patient’s lungs. Abovementioned factors are anticipated to support the segment development
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The asthma segment held the dominant share in 2016. An effective inhalation therapy that uses DPIs and MDIs is considered to be the basis of asthma management. Owing to the high number of people affected by asthma, the demand, and usage of devices such as MDIs and DPIs for asthma management are increasing, boosting the growth of this application.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The dynamic growth of the COPD segment can be attributed to the high incidence and mortality of this disease. Favorable reimbursement policies for the treatment of COPD and a rise in the number of government and non-government organizations that provide COPD treatment are increasing revenue generated by this segment. Owing to these factors, the COPD segment is expected to grow consistently.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Treatment of allergic rhinitis involves the use of nasal sprays, dry powder inhalers, and allergy shots. According to the National Center for Health Statistics (NCHS), in 2016, 20 million adults aged more than 18 years and 6.1 million children in the U.S. were diagnosed with allergic rhinitis. Due to a large patient pool, the demand for PDDS devices is projected to increase, resulting in the development of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The other application segment is anticipated to exhibit progress owing to the rise in patients diagnosed with various chronic diseases. According to the CDC, in 2016, 29.4 million adults were diagnosed with sinusitis in the U.S. Treatment of such diseases demands the use of PDDS. These factors are expected to provide this segment growth opportunity.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Distribution Channel Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospital pharmacies segment held the dominant share of the PDDS in 2016 and is projected to continue its dominance in the future. Hospitals provide extensive treatments, care, quick reimbursements, and insurance policies owing to which patients prefer hospital pharmacies. Furthermore, an increased number of hospitalizations is expected to boost the growth of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Retail pharmacies are expected to show steady growth over the future period, owing to easy accessibility and affordability. Hospitals and clinics rely on retail pharmacies as a backup for medications. Moreover, most of the home care products are available in retail pharmacies. These factors are likely to be responsible for the constant growth of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • E-commerce is anticipated to grow at a CAGR of 5.4% during the forecast period. Various factors such as improving healthcare infrastructure in developing regions and convenience of purchasing in comparison to retail or hospital pharmacies have supported the growth of this distribution channel to a great extent.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The trend of online purchasing and the demand for it is growing due to comfort, flexibility, and convenience, which is increasing the revenue generated by this segment. Moreover, online shopping offers discounts that benefit customers. These factors are expected to collectively boost the demand for online pharmacies.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • End-use Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • As of 2016, hospitals accounted for the largest revenue share of the PDDS. Hospitals are currently advancing in terms of technology usage. Technologically advanced medical devices are being extensively used in hospitals to improve point-of-care. Furthermore, hospitals also provide a wide array of treatments for various respiratory diseases.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In developed regions such as North America and Europe, hospitals also provide quick reimbursements for COPD treatment under the Medicare program. These facts are expected to stimulate the utilization of PDDS devices in hospital settings, leading to growth.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The home care segment is expected to exhibit lucrative growth over the future period. Growing preference for home healthcare is expected to boost the use of PDDS devices in home care settings. An increase in the cost of health care services and a shortage of healthcare facilities have also led to an increase in demand for home care services.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The introduction of technologically advanced devices, which are portable and small-sized, has resulted in patients using such products at home. These devices are convenient, easy-to-use, and do not require any special training to operate. These associated advantages are expected to increase the adoption of PDDS in home care, thereby boosting the growth of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Regional Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America held the dominant share of PDDS and was valued at USD 14.9 billion in 2016. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. A rise in the number of patients affected by these diseases, increases the demand for diagnostic devices, such as PDDS, thereby boosting the growth of this region.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In addition, the local presence of key pharmaceutical and medical devices players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America respiratory drug delivery devices market.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific region is anticipated to grow at an exponential rate of 6.2% due to the high prevalence of COPD, which indicates a substantial socioeconomic burden in this region. Continuous increase in the number of asthmatic and allergic rhinitis patients is also a major factor that is anticipated to propel the market demand for PDDS in the Asia Pacific region during the forecast period.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Furthermore, a rise in the number of supportive nongovernment organizations, such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), is estimated to increase awareness about the treatment of respiratory disorders amongst patients, leading to market growth. Continuous increase in R&D activities by key market players to develop novel respiratory devices is also expected to support the growth of the Asia Pacific region.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Product
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Metered Dose Inhalers
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Dry Powder Inhalers
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Nebulizers
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  •  Mesh
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Vibrating
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Static
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Pneumatic
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Vented
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Breath Actuated
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Ultrasonic
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Accessories
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asthma
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cystic Fibrosis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • COPD
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Allergic Rhinitis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Distribution Channel
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Retail Pharmacies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospital Pharmacies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • E-Commerce
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By End-use
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospitals & Clinics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Homecare
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Region
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Middle East and Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY PLAYERS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • GlaxoSmithKline plc
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Philips Respironics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Boehringer Ingelheim GmbH
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Novartis AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • 3M Healthcare
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • GF Health Products, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Merck & Co., Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • AstraZeneca
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the Pulmonary Drug Delivery Systems Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Pulmonary Drug Delivery Systems Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Pulmonary Drug Delivery Systems Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Pulmonary Drug Delivery Systems Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

The global market for Pulmonary Drug Delivery Systems was estimated to be valued at US$ XX Mn in 2021.

The global Pulmonary Drug Delivery Systems Market is estimated to grow at a CAGR of XX% by 2028.

The global Pulmonary Drug Delivery Systems Market is segmented on the basis of Product, Application, Distribution Channel, End-use, Region.

Based on region, the global Pulmonary Drug Delivery Systems Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the global Pulmonary Drug Delivery Systems Market are involved in the development of novel MDIs and the high acceptance rate of these devices in developing regions, such as Asia Pacific and Latin America, are some of the factors responsible for the revenue generated by this segment., Dry Powder Inhaler (DPI) segment is anticipated to grow at a lucrative rate during the future period. Advantages such as cost-effectiveness, short administration, and preparation time, and others are anticipated to increase the use of these inhalers by end users. Due to technological advancements, DPI emerged as a preferred medical device for the treatment of a diverse range of respiratory disorders, which has in turn increased the utilization of these products. The abovementioned factors are likely to propel the growth of this segment., Nebulizers are projected to grow at a steady rate over the future period. These devices are the most frequently used inhalation devices in hospitals. Nebulizers have a high adoption rate in home care and emergency medicine due to their benefits, such as greater comfort, administration of large dosage, and favorable reimbursement scenario, which is expected to help maintain a steady demand for this product segment., The accessories segment is estimated to grow at a CAGR of 5.6% owing to the launch of new products and extensive R&D in this field. These products are necessary for efficient drug delivery to a patient’s lungs. Abovementioned factors are anticipated to support the segment development, Application Insights, The asthma segment held the dominant share in 2016. An effective inhalation therapy that uses DPIs and MDIs is considered to be the basis of asthma management. Owing to the high number of people affected by asthma, the demand, and usage of devices such as MDIs and DPIs for asthma management are increasing, boosting the growth of this application., The dynamic growth of the COPD segment can be attributed to the high incidence and mortality of this disease. Favorable reimbursement policies for the treatment of COPD and a rise in the number of government and non-government organizations that provide COPD treatment are increasing revenue generated by this segment. Owing to these factors, the COPD segment is expected to grow consistently., Treatment of allergic rhinitis involves the use of nasal sprays, dry powder inhalers, and allergy shots. According to the National Center for Health Statistics (NCHS), in 2016, 20 million adults aged more than 18 years and 6.1 million children in the U.S. were diagnosed with allergic rhinitis. Due to a large patient pool, the demand for PDDS devices is projected to increase, resulting in the development of this segment., The other application segment is anticipated to exhibit progress owing to the rise in patients diagnosed with various chronic diseases. According to the CDC, in 2016, 29.4 million adults were diagnosed with sinusitis in the U.S. Treatment of such diseases demands the use of PDDS. These factors are expected to provide this segment growth opportunity., Distribution Channel Insights, Hospital pharmacies segment held the dominant share of the PDDS in 2016 and is projected to continue its dominance in the future. Hospitals provide extensive treatments, care, quick reimbursements, and insurance policies owing to which patients prefer hospital pharmacies. Furthermore, an increased number of hospitalizations is expected to boost the growth of this segment., Retail pharmacies are expected to show steady growth over the future period, owing to easy accessibility and affordability. Hospitals and clinics rely on retail pharmacies as a backup for medications. Moreover, most of the home care products are available in retail pharmacies. These factors are likely to be responsible for the constant growth of this segment., E-commerce is anticipated to grow at a CAGR of 5.4% during the forecast period. Various factors such as improving healthcare infrastructure in developing regions and convenience of purchasing in comparison to retail or hospital pharmacies have supported the growth of this distribution channel to a great extent., The trend of online purchasing and the demand for it is growing due to comfort, flexibility, and convenience, which is increasing the revenue generated by this segment. Moreover, online shopping offers discounts that benefit customers. These factors are expected to collectively boost the demand for online pharmacies., End-use Insights, As of 2016, hospitals accounted for the largest revenue share of the PDDS. Hospitals are currently advancing in terms of technology usage. Technologically advanced medical devices are being extensively used in hospitals to improve point-of-care. Furthermore, hospitals also provide a wide array of treatments for various respiratory diseases., In developed regions such as North America and Europe, hospitals also provide quick reimbursements for COPD treatment under the Medicare program. These facts are expected to stimulate the utilization of PDDS devices in hospital settings, leading to growth., The home care segment is expected to exhibit lucrative growth over the future period. Growing preference for home healthcare is expected to boost the use of PDDS devices in home care settings. An increase in the cost of health care services and a shortage of healthcare facilities have also led to an increase in demand for home care services., The introduction of technologically advanced devices, which are portable and small-sized, has resulted in patients using such products at home. These devices are convenient, easy-to-use, and do not require any special training to operate. These associated advantages are expected to increase the adoption of PDDS in home care, thereby boosting the growth of this segment., Regional Insights, North America held the dominant share of PDDS and was valued at USD 14.9 billion in 2016. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. A rise in the number of patients affected by these diseases, increases the demand for diagnostic devices, such as PDDS, thereby boosting the growth of this region., In addition, the local presence of key pharmaceutical and medical devices players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America respiratory drug delivery devices market., Asia Pacific region is anticipated to grow at an exponential rate of 6.2% due to the high prevalence of COPD, which indicates a substantial socioeconomic burden in this region. Continuous increase in the number of asthmatic and allergic rhinitis patients is also a major factor that is anticipated to propel the market demand for PDDS in the Asia Pacific region during the forecast period., Furthermore, a rise in the number of supportive nongovernment organizations, such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), is estimated to increase awareness about the treatment of respiratory disorders amongst patients, leading to market growth. Continuous increase in R&D activities by key market players to develop novel respiratory devices is also expected to support the growth of the Asia Pacific region., KEY MARKET SEGMENTS, By Product, Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers,  Mesh, Vibrating, Static, Pneumatic, Vented, Breath Actuated, Ultrasonic, Accessories, By Application, Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis, Others, By Distribution Channel, Retail Pharmacies, Hospital Pharmacies, E-Commerce, By End-use, Hospitals & Clinics, Homecare, By Region, North America, Europe, Asia Pacific, Latin America, Middle East and Africa, KEY PLAYERS, GlaxoSmithKline plc, Philips Respironics, Boehringer Ingelheim GmbH, Novartis AG, 3M Healthcare, GF Health Products, Inc., Merck & Co., Inc., AstraZeneca.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Pulmonary Drug Delivery Systems Market

Product ID: UCMIG35I2122

$5,300
BUY NOW GET SAMPLE